Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Welgene Biotech CoROCO:6661 70 PB Ratio is 1.45 as of Jul. 23, 2026, which is 21% below its 10-year median of 1.84. GuruFocus rates ROCO:6661 with a GF Score™ of 70/100 and a GF Value™ of NT$29.93 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Welgene Biotech Co ranks better than 65.64% on this metric.
The historical rank and industry rank for Welgene Biotech Co's PB Ratio or its related term are showing as below:
ROCO:6661'
s PB Ratio Range Over the Past 10 Years
Min: 1.31 Med: 1.84 Max: 3.23
Current: 1.45
During the past 12 years, Welgene Biotech Co's highest PB Ratio was 3.23. The lowest was 1.31. And the median was 1.84.
ROCO:6661's PB Ratio is ranked better than 65.64% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 2
vs ROCO:6661: 1.45
During the past 12 months, Welgene Biotech Co's average Book Value Per Share Growth Rate was -2.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -2.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -0.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 2.60% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Welgene Biotech Co was 25.10% per year. The lowest was -2.50% per year. And the median was 3.80% per year.
Back to Basics: PB Ratio
Welgene Biotech Co (ROCO:6661) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Welgene Biotech Co PB Ratio Related Terms
Welgene Biotech Co PB Ratio Historical Data
* Premium members only.
The historical data trend for Welgene Biotech Co's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Welgene Biotech Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Welgene Biotech Co PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Welgene Biotech Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Welgene Biotech Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Welgene Biotech Co (ROCO:6661) has a PB Ratio of 1.45 as of Jul. 23, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Welgene Biotech Co and its competitors. This is 21% below median its historical median of 1.84. Over the past decade, Welgene Biotech Co's PB Ratio has ranged from 1.31 to 3.23. According to the industry distribution chart, Welgene Biotech Co ranks #67 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 34.4%.
Is Welgene Biotech Co's PB Ratio too high?
Welgene Biotech Co's current PB Ratio of 1.45 is 21% below median its 10-year median of 1.84. Over the past 10 years, this metric has ranged from a low of 1.31 to a high of 3.23. The Medical Diagnostics & Research industry median PB Ratio is 2.00. Welgene Biotech Co's value of 1.45 is 27.5% below this industry median. Based on the distribution chart, Welgene Biotech Co ranks #67 out of 195 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Welgene Biotech Co has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Welgene Biotech Co's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Welgene Biotech Co ranks #67 out of 195 companies for PB Ratio. This puts Welgene Biotech Co in the upper half of its industry. The industry median PB Ratio is 2.00. Welgene Biotech Co's value of 1.45 is 27.5% below this benchmark. Historically, Welgene Biotech Co's own PB Ratio has ranged from 1.31 to 3.23 over the past decade. While the company's 10-year median is 1.84 vs. the industry median of 2.00, Welgene Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.00, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Welgene Biotech Co's current PB Ratio of 1.45 is 27.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Welgene Biotech Co and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Welgene Biotech Co's current PB Ratio is 1.45, which is 21% below median its own 10-year median of 1.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Welgene Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Welgene Biotech Co (ROCO:6661) is currently considered Possible Value Trap. The stock's GF Value™ is NT$29.93, compared to a current price of NT$17.55 — trading 41.4% below its estimated fair value. The current PB Ratio is 1.45, which is 21% below median its 10-year median of 1.84 and 27.5% below the Medical Diagnostics & Research industry median of 2.00. Welgene Biotech Co's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Welgene Biotech Co (ROCO:6661), the current PB Ratio is 1.45 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Welgene Biotech Co (ROCO:6661) Overvalued in 2026?
Based on GuruFocus' analysis, Welgene Biotech Co stock appears to be undervalued.
The current stock price of NT$17.55 is trading 41.4% below its estimated GF Value™ of NT$29.93.
GuruFocus considers Welgene Biotech Co to be Possible Value Trap.
Key valuation signals for ROCO:6661:
PB Ratio: 1.45 (21% below median its 10-year median of 1.84)
GF Value™: NT$29.93 vs. price of NT$17.55 (41.4% below fair value)
Industry Position: 27.5% below the Medical Diagnostics & Research median (#67 of 195)
No single metric tells the full story. See the ROCO:6661 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Welgene Biotech Co Ltd is engaged in providing genetic and biotechnology testing services and related products. Its offerings include next-generation sequencing (NGS) services, DNA microarray and PCR-based testing solutions, biotechnology reagents, diagnostic products, and laboratory instruments. The company also engages in the trading of medical and biotechnology equipment.
70GF Score
Get the complete analysis for ROCO:6661
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6661 has been successfully added to your 
